FNY - ETF AI Analysis
Top Page
First Trust Mid Cap Growth AlphaDEX Fund (FNY)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Year-To-Date Performance
The fund has delivered strong gains so far this year, which suggests its strategy and holdings have been working well in the recent market environment.
Strong-Performing Top Holdings
Many of the ETF’s largest positions, including several health care and consumer names, have shown strong performance this year, helping support the fund’s overall returns.
Broad Sector Diversification Within Mid-Caps
The ETF spreads its investments across many sectors such as health care, industrials, technology, and consumer companies, which helps reduce the impact if any single industry weakens.
Negative Factors
Higher Expense Ratio
The fund’s expense ratio is relatively high compared with many index-based ETFs, which means more of your returns go toward fees.
Recent Short-Term Weakness
The ETF has shown weak performance over the past month, indicating that returns can be volatile over shorter periods.
Heavy U.S. Market Concentration
Almost all of the ETF’s holdings are in U.S. companies, offering little geographic diversification if the U.S. market faces a downturn.
FNY vs. SPDR S&P 500 ETF (SPY)
AUM562.64M
RegionNorth America
Expense Ratio0.73%
Beta1.08
IssuerFirst Trust
Inception DateApr 19, 2011
Dividend YieldN/A
Asset ClassEquity
Index TrackedNASDAQ AlphaDEX Mid Cap Growth Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume11,648
30 Day Avg. Volume20,459
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
132.86Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering224
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FNY Summary
The First Trust Mid Cap Growth AlphaDEX Fund (FNY) is an ETF that follows the NASDAQ AlphaDEX Mid Cap Growth Index, focusing on medium‑sized U.S. companies with strong growth potential. It spreads investments across many sectors, including health care, industrials, and technology. Well-known names in the fund include Etsy and Victoria’s Secret. Someone might invest in FNY to seek long-term growth and diversify beyond just large, well-known companies. A key risk is that mid-sized growth stocks can be more volatile, so the ETF’s value can rise and fall more sharply than the overall market.
How much will it cost me?The expense ratio for the First Trust Mid Cap Growth AlphaDEX Fund (FNY) is 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because the fund is actively managed, using a specialized methodology to select and weight stocks for potential growth. Active management typically involves higher costs compared to passively managed funds that track an index.
What would affect this ETF?The First Trust Mid Cap Growth AlphaDEX Fund (FNY) could benefit from positive trends in the U.S. economy, such as technological advancements and increased demand for industrial and healthcare innovations, given its strong exposure to these sectors. However, it may face challenges from rising interest rates, which can negatively impact growth-focused companies, and potential economic slowdowns that could reduce consumer spending and affect cyclical sectors. Regulatory changes or geopolitical tensions could also influence the performance of its top holdings in industries like energy and materials.
FNY Top 10 Holdings
FNY is leaning hard into U.S. mid-cap growth, with health care and consumer names setting the tone. Corcept Therapeutics has been the star of the show, powering higher and giving the fund a strong health care tailwind, while Halozyme and Guardant Health add more rising biotech exposure. On the consumer side, Victoria’s Secret has quietly helped performance, but Etsy’s mixed, recently lagging action shows that not every retail name is firing on all cylinders. Overall, the fund is spread across many names, but its story is driven by a handful of surging mid-cap health care and retail stocks.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Zeta Global Holdings Corp | 1.01% | $5.70M | $7.74B | 43.93% | 67 Neutral | |
| Guardant Health | 1.00% | $5.64M | $23.47B | 211.39% | 61 Neutral | |
| Halozyme | 0.92% | $5.18M | $12.31B | 43.04% | 73 Outperform | |
| Okta | 0.91% | $5.15M | $32.89B | 103.01% | 75 Outperform | |
| Corcept Therapeutics | 0.87% | $4.88M | $12.09B | 42.65% | 76 Outperform | |
| Amneal Pharmaceuticals | 0.87% | $4.88M | $5.77B | 86.34% | 58 Neutral | |
| Coca-Cola Bottling Co Consolidated | 0.86% | $4.82M | $13.22B | 77.79% | 72 Outperform | |
| Tutor Perini | 0.85% | $4.77M | $4.51B | 29.37% | 65 Neutral | |
| TG Therapeutics | 0.84% | $4.75M | $8.55B | 73.17% | 65 Neutral | |
| frontdoor | 0.84% | $4.73M | $5.55B | 18.52% | 72 Outperform |
FNY Technical Analysis
Negative
―
Price Trends
103.57
Negative
103.95
Negative
99.39
Positive
Market Momentum
-1.45
Positive
38.69
Neutral
16.72
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FNY, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 101.94, equal to the 50-day MA of 103.57, and equal to the 200-day MA of 99.39, indicating a neutral trend. The MACD of -1.45 indicates Positive momentum. The RSI at 38.69 is Neutral, neither overbought nor oversold. The STOCH value of 16.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FNY.
FNY Peer Comparison
Comparison Results
Performance Comparison
FNY
First Trust Mid Cap Growth AlphaDEX Fund
99.53
7.30
7.91%
NUMG
Nuveen ESG Mid-Cap Growth ETF
―
―
―
RFG
Invesco S&P Midcap 400 Pure Growth ETF
―
―
―
GLRY
Inspire Faithward Mid Cap Momentum ESG ETF
―
―
―
FRTY
Alger Mid Cap 40 ETF
―
―
―
TMFM
Motley Fool Mid-Cap Growth ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents